Boston Scientific Work in process increased by 12.4% to $245.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 18.9%, from $206.00M to $245.00M. Over 4 years (FY 2020 to FY 2024), Work in process shows an upward trend with a 15.4% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase may indicate production bottlenecks or scaling efforts, while a decrease suggests efficient throughput or reduced manufacturing activity.
Represents the value of goods that have entered the production process but are not yet finished. For a manufacturer like...
Peers in medical device manufacturing typically maintain lean WIP levels to optimize cash conversion cycles.
inv_work_in_progress| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $121.00M | $127.00M | $128.00M | $142.00M | $144.00M | $149.00M | $147.00M | $176.00M | $175.00M | $187.00M | $174.00M | $188.00M | $201.00M | $206.00M | $193.00M | $218.00M | $218.00M | $245.00M |
| QoQ Change | — | +5.0% | +0.8% | +10.9% | +1.4% | +3.5% | -1.3% | +19.7% | -0.6% | +6.9% | -7.0% | +8.0% | +6.9% | +2.5% | -6.3% | +13.0% | +0.0% | +12.4% |
| YoY Change | — | — | — | — | +19.0% | +17.3% | +14.8% | +23.9% | +21.5% | +25.5% | +18.4% | +6.8% | +14.9% | +10.2% | +10.9% | +16.0% | +8.5% | +18.9% |
| % of Inventories | 8.5% | 7.9% | 8.0% | 8.2% | 8.2% | 8.3% | 7.9% | 8.6% | 7.8% | 7.8% | 7.0% | 7.3% | 7.7% | 7.5% | 6.9% | 7.6% | 7.6% | 8.4% |
| Share Change | — | -0.5pp | +0.0pp | +0.2pp | +0.0pp | +0.1pp | -0.5pp | +0.7pp | -0.8pp | +0.0pp | -0.8pp | +0.3pp | +0.4pp | -0.2pp | -0.6pp | +0.7pp | +0.0pp | +0.8pp |